SK Bioscience Co

SK Bioscience Co Gross Margin

The Gross Margin of SK Bioscience Co (302440.KS) as of Oct 23, 2026 is 25.63 %. In the previous year, Gross Margin was 11.58 % — a change of 121.37% (higher).

Gross Margin

25.63 %

YoY

121.37%

Last updated:

Gross Margin of SK Bioscience Co is 2025 25.63 % . Gross Margin of SK Bioscience Co was 2024 11.58 % . It decreases by 121.37% higher compared to the previous year.

SK Bioscience Co's gross margin stands at 26.0%, down from 61.6% several years earlier.

The SK Bioscience Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
44.48 KRW
Jan 1, 2019
43.30 KRW
Jan 1, 2020
42.26 KRW
Jan 1, 2021
61.39 KRW
Jan 1, 2022
52.46 KRW
Jan 1, 2023
38.50 KRW
Jan 1, 2024
11.58 KRW
Jan 1, 2025
25.63 KRW
The SK Bioscience Co Gross Margin history
YEARGross MarginYoY
25.63 %+121.37%
11.58 %-69.92%
38.50 %-26.62%
52.46 %-14.54%
61.39 %+45.26%
42.26 %-2.40%
43.30 %-2.65%
44.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SK Bioscience Co stock

Gross Margin of SK Bioscience Co is 25.63 % in 2025.

Gross Margin of SK Bioscience Co changed from 11.58 % to 25.63 %, representing a 121.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's SK Bioscience Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — SK Bioscience Co

All Key Metrics — SK Bioscience Co